A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Biochemical Pharmacology

Volumn 61, Issue 3, 2001, Pages 277-284

  Vauquelin, Georges ^a   Morsing, Peter ^b   Fierens, Frederik L P ^a   De Backer, Jean Paul ^a   Vanderheyden, Patrick M L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

AT1 antagonists; Candesartan; CHO cells; EXP3174; In surmountable; Inositol phosphate; Irbesartan; Losartan; Surmountable

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; INOSITOL PHOSPHATE; IRBESARTAN; LOSARTAN;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; INOSITOL PHOSPHATES; KINETICS; LOSARTAN; MODELS, BIOLOGICAL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0035254652     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00546-3     Document Type: Article

References (32)

1. Angiotensin antagonists
2. 1 receptor
3. 1 receptors
4. 1 receptor-transfected Chinese hamster ovary cells
5. 1 receptor antagonists: The role of tight antagonist binding
6. Quantitative studies on antagonists for 5-hydroxytryptamine
7. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action
8. 1 subtype angiotensin II receptor antagonist
9. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist
10. 1-receptor blockers in isolated vessels of different origin
11. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
12. The serotonin-S2 receptor: A receptor, transducer coupling model to explain insurmountable antagonist effects
13. Nonpeptide angiotensin receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent
14. Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model
15. 1 receptor antagonist
16. 1 antagonism
17. Different types of antiogensin II receptor antagonism induced by S 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve
18. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, R 277
19. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174
20. 1 receptor antagonist
21. 1 receptor antagonist
22. 1 receptor
23. 1-receptor subtype
24. 3H]irbesartan to human recombinant angiotensin type 1 receptors
25. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors
26. 1 angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands
27. Differentiation between binding sites for angiotensin II and non-peptide antagonists on the angiotensin II type 1 receptors
28. Nonpeptide angiotensin II receptor antagonists: Insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753
29. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients
30. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
31. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan study investigators
32. Pharmacokinetic-pharmacodynamic interactions of candesartan and losartan